Pharmacology and potential mechanisms of action of rizatriptan

被引：17

作者：

Hargreaves, RJ ^{[1
]}

机构：

[1] Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England

来源：

CEPHALALGIA | 2000年 / 20卷

关键词：

D O I：

10.1046/j.1468-2982.2000.020s1002.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：2 / 9

页数：8

共 13 条

[1] Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist [J].

Cumberbatch, MJ ;

Williamson, DJ ;

Mason, GS ;

Hill, RG ;

Hargreaves, RJ .

BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (06) :1478-1486

[2] Rizatriptan has central antinociceptive effects against durally evoked responses [J].

Cumberbatch, MJ ;

Hill, RG ;

Hargreaves, RJ .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 328 (01) :37-40

[3] Pharmacokinetics of rizatriptan tablets during and between migraine attach [J].

Cutler, NR ;

Jhee, SS ;

Majumdar, AK ;

McLoughlin, D ;

Brucker, MJ ;

Carides, AD ;

Kramer, MS ;

Matzura-Wolfe, D ;

Reines, SA ;

Goldberg, MR .

HEADACHE, 1999, 39 (04) :264-269

[4]

EVANS DC, 1999, CENTRAL SITES ACTION

[5] Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system:: Implications for the discovery of new antimigraine drugs [J].

Longmore, J ;

Shaw, D ;

Smith, D ;

Hopkins, R ;

McAllister, G ;

Pickard, JD ;

Sirinathsinghji, DJS ;

Butler, AJ ;

Hill, RG .

CEPHALALGIA, 1997, 17 (08) :833-842

[6] 5-HT1D receptor agonists and human coronary artery reactivity in vitro: Crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519 [J].

Longmore, J ;

Boulanger, CM ;

Desta, B ;

Hill, RG ;

Schofield, WN ;

Taylor, AA .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (04) :431-441

[7]

Longmore J, 1998, BRIT J CLIN PHARMACO, V46, P577

[8] Experimental cranial pain elicited by capsaicin:: a PET study [J].

May, A ;

Kaube, H ;

Büchel, C ;

Eichten, C ;

Rijntjes, M ;

Jüptner, M ;

Weiller, C ;

Diener, HC .

PAIN, 1998, 74 (01) :61-66

[9] Initial human experience with MK-462 (rizatriptan): A novel 5-HT1D agonist [J].

Sciberras, DG ;

Polvino, WJ ;

Gertz, BJ ;

Cheng, HY ;

Stepanavage, M ;

Wittreich, J ;

Olah, T ;

Edwards, M ;

Mant, T .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (01) :49-54

[10] Coronary side-effect potential of current and prospective antimigraine drugs [J].

VanDenBrink, AM ;

Reekers, M ;

Bax, WA ;

Ferrari, MD ;

Saxena, PR .

CIRCULATION, 1998, 98 (01) :25-30

← 1 2 →